NCT05329155 (HELP-PCI) is a NA clinical trial of Heparin Sodium Injection in STEMI, sponsored by Renmin Hospital of Wuhan University.

Who is sponsoring NCT05329155?

NCT05329155 is sponsored by Renmin Hospital of Wuhan University.

What drugs are being tested in NCT05329155?

Interventions in NCT05329155: Heparin Sodium Injection.

What condition does NCT05329155 study?

NCT05329155 studies STEMI, Primary PCI.

Is NCT05329155 still recruiting?

NCT05329155 is currently completed. Last updated 27 March 2025.

Last reviewed 2025-03-27 · How we verify

NCT05329155: HELP-PCI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Administration of Heparin At FMC for PPCI of STEMI Patients

Completed NA Last updated 27 March 2025

What this trial tests

NA trial testing Heparin Sodium Injection in STEMI in 1,145 participants. Completed in 20 August 2024.

Timeline

20 July 2022

Primary endpoint
20 August 2023

20 August 2024

Quick facts

Lead sponsor	Renmin Hospital of Wuhan University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,145
Start date	20 July 2022
Primary completion	20 August 2023
Estimated completion	20 August 2024
Sites	1 location across China

Drugs / interventions tested

Heparin Sodium Injection

Conditions studied

STEMI — all drugs for STEMI →
Primary PCI — all drugs for Primary PCI →

Sponsor

Renmin Hospital of Wuhan University

Who can join

Adults 18 to 80, any sex, with STEMI or Primary PCI. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied. Previous study revealed early use of antithrombotic drugs could improve patient's survival. Here we supposed that use of heparin at first medical contact could increase the TIMI flow 3 grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than in Cathlab.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Heparin administration at first medical contact vs immediately before primary percutaneous coronary intervention: the HELP-PCI trial.
Chen J, Xu C, Qiu L, Li B, et al · · 2025 · cited 3× · PMID 40748607 · DOI 10.1093/eurheartj/ehaf481

Verify or expand the search:

Other trials of Heparin Sodium Injection

Trials testing the same drug.

NCT06869291 — Observation of the Effect and Mechanism of Multi Tunnel Minimally Invasive Treatment for Xanthelasma Palpebrarum · NA · enrolling by invitation
NCT06365398 — Safety and Efficacy of Low-dose hEparinization in Cerebral Angiography sTudy · Phase 4 · completed

Other recruiting trials for STEMI

Currently open trials in the same condition.

NCT06966674 — No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track · NA · recruiting
NCT06678074 — Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI · Phase 1, PHASE2 · active not recruiting
NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
NCT06528821 — AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS · active not recruiting
NCT07026708 — TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevat · recruiting

Other Renmin Hospital of Wuhan University trials

Trials by the same sponsor.

NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05329155 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
Last refreshed: 27 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05329155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing